Drug Profile

Avipendekin pegol - Nektar Therapeutics

Alternative Names: NKTR-255; Polymer-conjugated IL-15 - Nektar Therapeutics

Latest Information Update: 28 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nektar Therapeutics
Developer AbelZeta Pharma; Fred Hutchinson Cancer Research Center; Gilead Sciences; Janssen; M. D. Anderson Cancer Center; Merck KGaA; Nektar Therapeutics; Stanford University
Class Antineoplastics; Antivirals; Immunotherapies; Interleukins; Recombinant fusion proteins
Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 15 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Phase II/III B-cell lymphoma; Diffuse large B cell lymphoma
Phase II Non-small cell lung cancer; Urogenital cancer
Phase I/II Cervical cancer; Colorectal cancer; Squamous cell cancer
Preclinical Triple negative breast cancer
No development reported Burkitt's lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Viral infections

28 Jan 2025 No recent reports of development identified for preclinical development in Burkitt's-lymphoma in USA (Parenteral)
28 Jan 2025 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in USA (Parenteral)
28 Jan 2025 No recent reports of development identified for preclinical development in Follicular lymphoma in USA (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com